Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity
Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I rate TEVA stock as a Strong Buy.
Why Teva Pharmaceuticals (TEVA) Crashed on Wednesday?
We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands among Wednesday’s worst-performing stocks.
Teva falls sharply on disappointing 2025 guidance
"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products and key innovative products," said Teva CEO.
Why Teva Pharmaceutical Industries Limited’s (TEVA) Stock Is Down 13.89%
Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is right time to buy.
Teva Pharmaceutical Stock Falls On Q4 Earnings: What's Going On?
Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of 71 cents per share,
Teva Pharmaceutical Shares Fall 13% Following Lower-than-Expected Q4 Results
Teva Pharmaceutical Industries Ltd. (TEVA) has seen a decline of 13.92 percent in its stock value during Wednesday afternoon trading
Teva Pharm tops quarterly estimates but 2025 earnings outlook falls short
Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in a trio of its branded drugs to treat migraines, Huntington's disease and schizophrenia.
Teva Pharmaceutical shares tumble as 2025 outlook disappoints
NEW YORK - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported fourth-quarter earnings that beat analyst estimates, but its shares fell sharply as the company's 2025 outlook came in below expectations.
Teva slips as 2025 earnings outlook misses estimates
Teva Pharmaceutical (NYSE:TEVA) lost ~5% in the premarket even after recording better-than-expected financials for Q4 2024 on Wednesday, as the generic drugmaker set its 2025 earnings outlook below consensus.
TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates
Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...
Teva Pharmaceutical Indus Options Trading: A Deep Dive into Market Sentiment
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Teva price target lowered to $26 from $28 at Barclays
Barclays lowered the firm’s price target on Teva (TEVA) to $26 from $28 and keeps an Overweight rating on the shares. The post-earnings selloff ...
Teva Swings to 4Q Loss as Revenue Falls
Teva Pharmaceutical Industries swung to a fourth-quarter loss on lower revenue and an operating loss. Shares fell about 2.5% in premarket trading to $20.99.
BofA cuts TEVA stock price target to $23, maintains Buy rating
BofA Securities made adjustments to its financial model for Teva Pharmaceutical Industries Ltd (NYSE:TEVA), resulting in a lowered price target. While the firm maintained a Buy rating on the stock, ...
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...
JD Supra2d
Teva Announces New Biosimilar Deals
Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...
Piper Sandler Remains a Buy on Teva Pharmaceutical (TEVA)
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...